FindTrial
Sign In

VRC-HIVDNA016-00-VP

BIOLOGICAL9 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

Adaptive ImmunityHIVHIV InfectionsHIV NegativeInnate Immunity

Phase 1

Candidate HIV Vaccine
CompletedNCT00089531
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
Start: 2004-08-02End: 2008-01-15Target: 15Updated: 2017-07-02
Prime-Boost Vaccine Schedule for Prevention of HIV Infection
CompletedNCT00109629
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
Start: 2005-04-26End: 2008-01-22Target: 40Updated: 2017-07-02
Safety of and Immune Response to an Adenoviral HIV Vaccine (VRC-HIVADV014-00-VP) With or Without a Plasmid HIV Vaccine (VRC-HIVDNA016-00-VP) in HIV Uninfected Adults
CompletedNCT00124007
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
Start: 2005-11-30End: 2007-04-30Updated: 2021-11-01
Safety of and Immune Response to an HIV-1 Vaccine (VRC-HIVDNA016-00-VP) and a Vaccine Booster (VRC-HIVADV014-00-VP) in HIV Uninfected East African Adults
CompletedNCT00123968
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
Start: 2006-05-31End: 2012-06-30Updated: 2021-11-09
Safety and Immune Response to a Prime-Boost Vaccination Schedule in HIV-infected Patients
CompletedNCT00270465
National Institute of Allergy and Infectious Diseases (NIAID)HIV
Start: 2005-12-21End: 2009-06-25Target: 17Updated: 2017-07-02
Immune Responses to Two Experimental HIV Vaccines in Healthy Adults
CompletedNCT01386489
National Institute of Allergy and Infectious Diseases (NIAID)Adaptive Immunity, HIV Negative, Innate Immunity
Start: 2011-06-17End: 2014-03-19Updated: 2019-12-16

Phase 2

HVTN Protocol 204 - A Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA016-00-VP, Followed by a Multiclade Recombinant Adenoviral Vector HIV-1 Vaccine Boost, VRCHIVADV014-00-VP, in HIV-1 Uninfected Adult Participants
CompletedNCT00125970
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
Start: 2005-09-30End: 2010-01-31Updated: 2021-10-15
Safety of and Immune Response to an HIV DNA Plasmid Vaccine Followed by HIV Adenoviral Vector Vaccine in Healthy African Adults
WithdrawnNCT00415649
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
Updated: 2021-11-01
Safety and Effectiveness of an HIV DNA Vaccine Followed by an HIV Adenoviral Vector Vaccine for Prevention of HIV Infection in the Americas and Africa
WithdrawnNCT00498056
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
Updated: 2021-11-01

Related Papers

Sequence and vector shapes vaccine induced antibody effector functions in HIV vaccine trials
PLoS Pathogens2021-11-292 citations
DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial.
2013-04-0860 citations
Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire.
2013-03-1244 citations
A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204).
2011-08-03117 citations
Reasons for ineligibility in phase 1 and 2A HIV vaccine clinical trials at Kenya AIDS vaccine initiative (KAVI), Kenya.
2011-01-2114 citations
Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa.
2010-09-2176 citations
A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172).
2010-02-0182 citations
Contraceptive use in women enrolled into preventive HIV vaccine trials: experience from a phase I/II trial in East Africa.
2009-04-1021 citations